Zepbound Shows Sustained Psoriasis Improvement in Phase 3b
LLY sits 64% above its 52-week low of $712.05.
Summary
Lilly reported 52-week Phase 3b data showing Zepbound combined with Taltz sustained superior improvements in psoriasis and psoriatic arthritis versus Taltz alone. The results extend prior 36-week findings with no new safety concerns. This supports label expansion for Zepbound into immunology, a new market beyond obesity and diabetes. The data could strengthen Lilly's case for broader reimbursement and differentiation against competitors. Watch for regulatory submissions and potential label updates.
At the time of this announcement, LLY was trading at $1,170.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.